Accelerate Diagnostics, Inc. (AXDX) Given Consensus Recommendation of “Buy” by Analysts

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has received an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and three have given a strong buy rating to the company.

Analysts have set a 12-month consensus price target of $25.00 for the company and are anticipating that the company will post ($0.37) EPS for the current quarter, according to Zacks. Zacks has also assigned Accelerate Diagnostics an industry rank of 147 out of 265 based on the ratings given to related companies.

AXDX has been the topic of several recent research reports. ValuEngine raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub cut shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 13th. BTIG Research reissued a “hold” rating on shares of Accelerate Diagnostics in a research report on Sunday, February 18th. Finally, Zacks Investment Research raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st.

In other news, Director Jack W. Schuler bought 20,000 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $24.95 per share, with a total value of $499,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jack W. Schuler bought 10,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $25.21 per share, for a total transaction of $252,100.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 210,100 shares of company stock worth $4,361,900. Insiders own 49.30% of the company’s stock.

Several institutional investors have recently bought and sold shares of AXDX. Lee Financial Co bought a new position in shares of Accelerate Diagnostics during the 1st quarter worth approximately $128,000. Cpwm LLC bought a new position in shares of Accelerate Diagnostics during the 4th quarter worth approximately $202,000. UBS Asset Management Americas Inc. bought a new position in shares of Accelerate Diagnostics during the 4th quarter worth approximately $233,000. Cowen Inc. purchased a new stake in shares of Accelerate Diagnostics during the 1st quarter worth approximately $267,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Accelerate Diagnostics during the 4th quarter worth approximately $292,000. 45.33% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ AXDX traded up $0.50 during trading hours on Thursday, hitting $22.15. The company’s stock had a trading volume of 383,301 shares, compared to its average volume of 253,123. Accelerate Diagnostics has a 52 week low of $20.45 and a 52 week high of $21.25. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -19.09 and a beta of 2.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 26.44 and a current ratio of 27.80.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings results on Wednesday, May 9th. The medical research company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.05. Accelerate Diagnostics had a negative net margin of 1,568.29% and a negative return on equity of 51.23%. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $2.64 million. sell-side analysts predict that Accelerate Diagnostics will post -1.38 EPS for the current year.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit